about
Interactions between HLA-G and HLA-E in Physiological and Pathological ConditionsNAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma ModelRecent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human DiseasesPlasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patientsCatastrophic relapse of Evans syndrome five years after allogeneic BMT notwithstanding full donor chimerism. Terminal hemolytic-uremic syndrome.A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis.Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins.Close interactions between mesenchymal stem cells and neuroblastoma cell lines lead to tumor growth inhibition.Dexamethasone prophylaxis in pediatric open heart surgery is associated with increased blood long pentraxin PTX3: potential clinical implications.Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients.Immunogenicity of human neuroblastoma.Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patientsSoluble HLA-G: Are they clinically relevant?PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillanceMechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients.Emerging topics and new perspectives on HLA-G.HLA-G in organ transplantation: towards clinical applications.Immunosuppressive microenvironment in neuroblastoma.The emerging role of soluble HLA-G in the control of chemotaxis.Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.Evaluation of bone marrow as a metastatic site of human neuroblastoma.IL-27 driven upregulation of surface HLA-E expression on monocytes inhibits IFN-γ release by autologous NK cells.Antibody mimicry, receptors and clinical applications.IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation.Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses.Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo.Human TCRγδ+ T cells represent a novel target for IL-27 activity.Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma.CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow.Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release.Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.Altered centrosomes in ataxia-telangiectasia cells and rapamycin-treated Chinese hamster cells.The role of HLA-class Ib molecules in immune-related diseases, tumors, and infections.Soluble HLA-G modulates miRNA-210 and miRNA-451 expression in activated CD4+ T lymphocytes.Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.CD4+CD25hiCD127- Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections 2016.
P50
Q21131161-0887ED99-15DE-4F97-8855-45181FFB2A44Q26782214-761AF6AF-1ED1-4C93-8D84-865CAA9AFC35Q28079536-1842453D-F78C-4131-A7AA-CFF4E00BBEF5Q28304289-EAE7BF47-70E5-4825-9A8B-CCD7103A8D80Q33373065-A17E9820-F4E6-4331-89F2-8262F71FE518Q33644555-AF274C75-0482-4193-A707-A98B97A9344DQ34130792-D411D808-729F-42D6-8C79-C4327830F8B4Q34465378-428658E1-86A2-427C-B5F3-ACADDDCAFBC0Q35110197-FFBE87E9-DC58-405B-935B-D35A05C09061Q35955285-E28E47EB-7F00-468C-8082-555A988D0DECQ36009145-F323CA2F-689A-4726-949E-364C48141327Q36184329-527289AD-0479-42EE-A1D8-02258C16D063Q36384011-70090277-62AE-405A-A0D0-537B7893E903Q36597354-DDE38357-346A-4356-9B83-A3E215410FCBQ36883879-A11DFA9D-0B15-40CF-BBFD-96618FFC3EDDQ37215353-FB725763-0BF2-4494-997E-D143D020CC8FQ37809764-D945FD6A-899C-4197-A4C4-EE259B2A6CAEQ37811950-A0D29C63-90E8-4931-AF40-6B37AC4F0654Q38117379-92698CEF-7739-4840-8DC5-DE4D1700F91DQ38216549-7D5F8303-2651-4E49-9872-862B107E449EQ38232436-78421BDD-2EFC-43E3-B39C-B8AFC110C180Q38260230-5BFCA441-E61C-4315-B361-9DD4869D9D38Q38772289-91042F15-DB96-407A-9C36-1B87F485ED45Q39062940-CE02E9B0-6135-4716-8B97-C7F8873F8947Q39247645-B97AED80-A0A5-43AF-9E9A-B424C0334CFDQ39266544-0A76C98E-1540-4190-AB4B-1A91B8236FA7Q39423588-071397BF-61B7-4305-BB64-6660AD23CE93Q39606012-0C4DC35B-B276-4566-8698-B5F18CC78891Q39646065-E0D7D0E0-678B-44B4-87EE-63D508EC400BQ40053162-EFE280E8-A6E3-4C9D-89EF-9591A29AEFCCQ40084964-F50A83DA-F9C9-4D0E-969E-191FE3142315Q40110163-179866DD-A0D4-4FAA-AC03-B63E802D7648Q40124595-06C03CBC-6611-413A-BD14-2F6506C1BC7FQ40190430-1C990623-040F-44F5-9E91-41AD2E8F3B54Q40416285-1FC6B7BA-1839-46BF-B95F-129A902171C3Q40735081-BE743F4F-8054-4888-B465-53005B1D97C3Q41510335-26BC9003-7561-4392-B713-E34897F36A3BQ41579154-F522FE06-2B4A-4ADE-A6CD-99A3707A6833Q42333778-085BD2C7-9C9D-4E27-B7D1-2FDBF3665152Q42408773-0E6ACE96-3916-4D52-AED7-7F1A94C09FA8
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabio Morandi
@ast
Fabio Morandi
@en
Fabio Morandi
@es
Fabio Morandi
@nl
Fabio Morandi
@sl
type
label
Fabio Morandi
@ast
Fabio Morandi
@en
Fabio Morandi
@es
Fabio Morandi
@nl
Fabio Morandi
@sl
prefLabel
Fabio Morandi
@ast
Fabio Morandi
@en
Fabio Morandi
@es
Fabio Morandi
@nl
Fabio Morandi
@sl
P106
P1153
8205758700
P21
P31
P496
0000-0002-2849-7595